Last reviewed · How we verify
Exemestane Tablets
Exemestane is a steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer.
Exemestane is a steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and extended therapy), Advanced or metastatic breast cancer in postmenopausal women.
At a glance
| Generic name | Exemestane Tablets |
|---|---|
| Sponsor | Tolmar Inc. |
| Drug class | Aromatase inhibitor (steroidal) |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Exemestane irreversibly inhibits the aromatase enzyme, which catalyzes the final step of estrogen biosynthesis in peripheral tissues. By reducing circulating estrogen levels, it deprives estrogen-dependent breast cancer cells of growth signals. This mechanism is particularly effective in postmenopausal women where peripheral aromatization is the primary source of estrogen.
Approved indications
- Hormone receptor-positive breast cancer in postmenopausal women (adjuvant and extended therapy)
- Advanced or metastatic breast cancer in postmenopausal women
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Nausea
- Headache
- Osteoporosis/bone loss
- Vaginal dryness
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) (PHASE2)
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (PHASE1)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (PHASE3)
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (PHASE2)
- A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery (NA)
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exemestane Tablets CI brief — competitive landscape report
- Exemestane Tablets updates RSS · CI watch RSS
- Tolmar Inc. portfolio CI